Literature DB >> 32147059

Preliminary evaluation of the clinical implementation of cognitive-behavioral therapy for chronic pain management in pediatric sickle cell disease.

Soumitri Sil1, Kristina Lai2, Jennifer L Lee3, Jordan Gilleland Marchak3, Beth Thompson3, Lindsey Cohen4, Peter Lane3, Carlton Dampier3.   

Abstract

OBJECTIVES: Evaluate the implementation of cognitive-behavioral therapy (CBT) for chronic pain in a clinical setting by comparing youth with sickle cell disease (SCD) who initiated or did not initiate CBT.
DESIGN: Youth with SCD (ages 6-18; n = 101) referred for CBT for chronic pain were compared based on therapy attendance: Established Care; Early Termination; or Comparison (i.e., did not initiate CBT).
SETTING: Outpatient pediatric psychology and comprehensive SCD clinics in 3 locations at a southeastern children's hospital.
INTERVENTIONS: CBT delivery was standardized. Treatment plans were tailored to meet individualized needs. MAIN OUTCOME MEASURES: Healthcare utilization included pain-related inpatient admissions, total inpatient days, and emergency department reliance (EDR) at 12-months pre-post CBT. Patient-reported outcomes (PROs) included typical pain intensity, functional disability, and coping efficacy pre-post treatment.
RESULTS: Adjusting for age, genotype, and hydroxyurea, early terminators of CBT had increased rates of admissions and hospital days over time relative to comparisons; those who established care had faster reduction in admissions and hospital days over time relative to comparisons. EDR decreased by 0.08 over time for Established Care and reduced by 0.01 for every 1 completed session. Patients who completed pre- and post-treatment PROs reported decreases in typical pain intensity, functional disability, and improved coping efficacy.
CONCLUSIONS: Establishing CBT care may support reductions in admissions for pain, length of stay, and EDR for youth with chronic SCD pain, which may be partially supported by patient-reported improvements in functioning, coping, and lower pain intensity following CBT. Enhancing clinical implementation of multidisciplinary treatments may optimize the health of these youth.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic pain; Cognitive-behavioral therapy; Healthcare utilization; Patient-reported outcomes; Sickle cell disease

Mesh:

Year:  2020        PMID: 32147059      PMCID: PMC7092728          DOI: 10.1016/j.ctim.2020.102348

Source DB:  PubMed          Journal:  Complement Ther Med        ISSN: 0965-2299            Impact factor:   2.446


  39 in total

1.  Evidence-Based Nonpharmacologic Strategies for Comprehensive Pain Care: The Consortium Pain Task Force White Paper.

Authors:  Heather Tick; Arya Nielsen; Kenneth R Pelletier; Robert Bonakdar; Samantha Simmons; Ronald Glick; Emily Ratner; Russell L Lemmon; Peter Wayne; Veronica Zador
Journal:  Explore (NY)       Date:  2018-03-01       Impact factor: 1.775

2.  New evidence regarding racial and ethnic disparities in mental health: policy implications.

Authors:  Thomas G McGuire; Jeanne Miranda
Journal:  Health Aff (Millwood)       Date:  2008 Mar-Apr       Impact factor: 6.301

3.  Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.

Authors:  John T Farrar; James P Young; Linda LaMoreaux; John L Werth; Michael R Poole
Journal:  Pain       Date:  2001-11       Impact factor: 6.961

4.  Medicaid and African American outpatient mental health treatment.

Authors:  L R Snowden; K Thomas
Journal:  Ment Health Serv Res       Date:  2000-06

5.  Chronic pain and its impact on quality of life in adolescents and their families.

Authors:  J A Hunfeld; C W Perquin; H J Duivenvoorden; A A Hazebroek-Kampschreur; J Passchier; L W van Suijlekom-Smit; J C van der Wouden
Journal:  J Pediatr Psychol       Date:  2001 Apr-May

6.  Emergency department reliance: a discriminatory measure of frequent emergency department users.

Authors:  Eric L Kroner; Raymond G Hoffmann; David C Brousseau
Journal:  Pediatrics       Date:  2009-12-14       Impact factor: 7.124

7.  Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations.

Authors:  Patrick J McGrath; Gary A Walco; Dennis C Turk; Robert H Dworkin; Mark T Brown; Karina Davidson; Christopher Eccleston; G Allen Finley; Kenneth Goldschneider; Lynne Haverkos; Sharon H Hertz; Gustaf Ljungman; Tonya Palermo; Bob A Rappaport; Thomas Rhodes; Neil Schechter; Jane Scott; Navil Sethna; Ola K Svensson; Jennifer Stinson; Carl L von Baeyer; Lynn Walker; Steven Weisman; Richard E White; Anne Zajicek; Lonnie Zeltzer
Journal:  J Pain       Date:  2008-06-17       Impact factor: 5.820

8.  The Pain Coping Questionnaire: preliminary validation.

Authors:  G J Reid; C A Gilbert; P J McGrath
Journal:  Pain       Date:  1998-05       Impact factor: 6.961

9.  The use of neuropathic pain drugs in children with sickle cell disease is associated with older age, female sex, and longer length of hospital stay.

Authors:  Amanda M Brandow; Rebecca A Farley; Mahua Dasgupta; Raymond G Hoffmann; Julie A Panepinto
Journal:  J Pediatr Hematol Oncol       Date:  2015-01       Impact factor: 1.289

Review 10.  Psychological therapies for the management of chronic and recurrent pain in children and adolescents.

Authors:  Emma Fisher; Emily Law; Joanne Dudeney; Tonya M Palermo; Gavin Stewart; Christopher Eccleston
Journal:  Cochrane Database Syst Rev       Date:  2018-09-29
View more
  2 in total

Review 1.  Advances in the diagnosis and treatment of sickle cell disease.

Authors:  A M Brandow; R I Liem
Journal:  J Hematol Oncol       Date:  2022-03-03       Impact factor: 17.388

2.  Effects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study.

Authors:  Samuel N Rodgers-Melnick; Lucas Lin; Kristina Gam; Evanilda Souza de Santana Carvalho; Coretta Jenerette; Douglas Y Rowland; Jane A Little; Jeffery A Dusek; Nitya Bakshi; Lakshmanan Krishnamurti
Journal:  J Pain Res       Date:  2022-01-11       Impact factor: 3.133

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.